Related Experiment Video
Updated: Jul 20, 2026
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
Ocular cicatricial pemphigoid
Melanie Hingorani1, Susan Lightman
1Department of Ophthalmology, Hinchingbrooke Hospital, Huntingdon, Cambridgeshire, UK. melanie.hingorani@hinchingbrooke.nhs.uk
Purpose Of Review:
To review the content and importance of articles on ocular cicatricial pemphigoid (OCP), or mucous membrane pemphigoid (MMP) with relevance to ocular involvement, published from 2005 to 2006.
Recent Findings:
There is wide antigenic heterogeneity in MMP and OCP and attempts are being made to link this with clinical variations with varying degrees of success. A larger study demonstrates a link between multiple autoantibody reactivity and disease severity. Details of epitope specificity are emerging. A highly sensitive ELISA for laminin 5 has been developed which may provide prognostic information.Clinically, younger OCP patients show more severe ocular disease and are less well controlled by medication. A systematic review shows good evidence only for steroids and cyclophosphamide in OCP. Continued small trials suggest some role for the expensive intravenous immunoglobulin therapy in OCP where conventional treatment fails. Ocular reconstruction surgery has made some progression, and is enhanced by adjunctive medical therapy; osteo-odonto-keratoprosthesis offers some hope of prolonged retention of limited vision in end-stage disease.
Summary:
OCP remains a difficult disease to manage well and the progress being made in understanding disease mechanisms is whence true disease-modifying, safe therapy is likely to emerge in the future.
Insights
Ocular cicatricial pemphigoid (OCP) is challenging to manage. Research is advancing understanding of its mechanisms, which may lead to better therapies for this autoimmune blistering disease affecting the eyes.
Area of Science:
- Ophthalmology
- Immunology
- Dermatology
Background:
- Ocular cicatricial pemphigoid (OCP), a subtype of mucous membrane pemphigoid (MMP), is a chronic autoimmune blistering disease.
- It primarily affects the mucous membranes, with significant ocular involvement leading to vision loss.
Purpose of the Study:
- To review recent literature (2005-2006) on OCP/MMP with ocular relevance.
- To assess the content, importance, and advancements in understanding and managing OCP.
Main Methods:
- Systematic review of published articles from 2005-2006.
- Analysis of antigenic heterogeneity, clinical variations, and treatment outcomes.
Main Results:
- Antigenic heterogeneity in MMP/OCP is noted, with emerging links to clinical variations and disease severity.
- Younger OCP patients exhibit more severe ocular disease and poorer treatment control.
- Steroids and cyclophosphamide are supported by good evidence; IVIg shows promise for refractory cases.
- Ocular reconstruction and osteo-odonto-keratoprosthesis offer surgical options for end-stage disease.
Conclusions:
- OCP remains a difficult condition to manage effectively.
- Advances in understanding disease mechanisms are crucial for developing future safe and disease-modifying therapies.
